A5076720762- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Inflammatory Biomarkers in Disease Prognosis
- Cancer Diagnosis and Treatment
- Gastrointestinal Tumor Research and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Renal cell carcinoma treatment
- Sarcoma Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Metastasis and carcinoma case studies
- Genetic factors in colorectal cancer
- Neutropenia and Cancer Infections
- HER2/EGFR in Cancer Research
- Colorectal and Anal Carcinomas
- Breast Cancer Treatment Studies
- Nutrition and Health in Aging
- Colorectal Cancer Surgical Treatments
Hacettepe University Hospital
2016-2025
Cancer Institute (WIA)
2016-2025
Hacettepe University
2015-2024
Kırıkkale University
2024
Ege University
2011-2023
Marmara University
2011-2023
Gülhane Askerî Tıp Akademisi
2023
Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi
2023
Afyon Kocatepe University
2023
Izmir University
2014-2023
Treatment options are limited for patients with previously treated metastatic colorectal cancer (mCRC). In the LEAP-017 study, we evaluate whether lenvatinib in combination pembrolizumab improves outcomes compared standard of care (SOC) mismatch repair proficient or not microsatellite instability high (pMMR MSI-H) mCRC.
Background The hemoglobin, albumin, lymphocyte, and platelet (HALP) score could be a prognostic biomarker in patients with cancer as reflector of nutritional inflammatory status, although the data is limited treated immune-checkpoint inhibitors (ICIs). Therefore, we sought to investigate relationship between HALP survival ICI-treated patients.
BACKGROUND The objectives of this study were to provide sunitinib patients with gastrointestinal stromal tumor (GIST) who otherwise unable obtain it and collect broad safety efficacy data from a large population advanced GIST after imatinib failure. (ClinicalTrials.gov identifier NCT00094029). METHODS Imatinibresistant/ intolerant received on an initial dosing schedule 50 mg daily in 6‐week cycles (4 weeks treatment, 2 off treatment). Tumor assessment frequency was according local practice,...
CUPISCO is an ongoing randomized phase II trial (NCT03498521) comparing molecularly guided therapy versus platinum-based chemotherapy in patients newly diagnosed with "unfavorable" cancer of unknown primary (CUP).Patients unfavorable CUP diagnosis, as defined by the European Society Medical Oncology (ESMO), and available tissue for molecular sequencing are generally eligible. Potential entering screening undergo a review involving reference histopathology clinical work-up central eligibility...
To investigate efficacy and safety of cetuximab combined with two chemotherapy regimens in patients unresectable metastatic colorectal cancer (mCRC).Randomized received 5-fluorouracil (5-FU), folinic acid (FA) oxaliplatin (FOLFOX) 6 (arm A, n = 74) or 5-FU, FA irinotecan (FOLFIRI) B, 77). KRAS mutation status was determined retrospectively a subset tumors (n 117).No significant difference found between treatment arms A B the progression-free survival (PFS) rate at 9 mo, 45% vs 34%; median...
Purpose: To evaluate the incidence, clinicopathological characteristics, treatment outcomes, prognostic factors, and survival of gastric cancer patients with bone metastases.Materials Methods: Of 4,617 who were treated between 2001 2013, 176 metastases analyzed.Results: The incidence metastasis was 3.8%.The most common histopathological subtype adenocarcinoma (79%) poor differentiation (60.8%).The median interval from diagnosis to 11 months.The time after 5.4 months.Factors that associated...
Background We compared the new outpatient clinic referrals during first 10 months of COVID-19 pandemic with year before. Methods baseline characteristics 2208 in 2020 (n=922) and 2019 (n=1286) Χ 2 Mann-Whitney U tests calculated ORs binary logistic regression. To evaluate expected changes cancer survival secondary to stage migration, we used 5-year data Survival, Epidemiology End Results (SEER) Program 2010–2016. The percentage patients inoperable or metastatic disease was significantly...
<b><i>Objective:</i></b> It was the aim of this study to evaluate maintenance therapy with bevacizumab + capecitabine following induction oxaliplatin (XELOX) versus XELOX until progression as first-line in metastatic colorectal cancer (mCRC). <b><i>Methods:</i></b> Patients received either (7.5 mg/kg) (capecitabine 1,000 mg/m<sup>2</sup> twice daily on days 1-14 130 day 1 every 3 weeks) disease (arm A) or same doses for 6 cycles...
Abstract Background This study aimed to evaluate the demographic,” clinicopathologic, and prognostic characteristics of malignant peritoneal mesothelioma (MPeM), as well treatment options for rare heterogeneous MPeM population. Methods A retrospective multi-center observational cohort was conducted patients with MPeM. Due heterogeneity population, divided them into two main groups in terms treatments, follow-up periods, features. The first group comprised who underwent cytoreductive surgery...
TPS326 Background: CodeBreaK 300 (NCT05198934) evaluated sotorasib, a selective inhibitor that irreversibly binds to the Kirsten rat sarcoma ( KRAS ) G12C mutant protein, in combination with panitumumab, an anti–epidermal growth factor receptor inhibitor, and showed 960 mg sotorasib + panitumumab provided statistically clinically significant improvement progression-free survival compared trifluridine/tipiracil or regorafenib patients chemorefractory metastatic colorectal cancer (mCRC) (1)....
Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for solid tumors, offering substantial survival benefits. Despite this progress, many patients do not achieve durable responses, highlighting need novel prognostic biomarkers. This study investigates association between serum sodium levels and outcomes in treated with ICIs. We conducted a retrospective cohort involving 509 metastatic tumors assessed overall (OS), progression-free (PFS), response rates using...